Magnetic Resonance Spectroscopy Features of the Visual Pathways in Patients with Glaucoma.
Adult
Age Factors
Aged
Aged, 80 and over
Aspartic Acid
/ analogs & derivatives
Case-Control Studies
Female
Geniculate Bodies
/ metabolism
Glaucoma
/ diagnosis
Humans
Intraocular Pressure
/ physiology
Magnetic Resonance Imaging
/ methods
Magnetic Resonance Spectroscopy
/ methods
Male
Middle Aged
Ocular Hypertension
/ metabolism
Visual Cortex
/ metabolism
Visual Pathways
/ metabolism
Young Adult
Corpus geniculatum laterale (CGL)
N‑acetyl aspartate (NAA)
Open angle glaucoma
Suspected glaucoma (GS)
Visual cortex (VC)
Journal
Clinical neuroradiology
ISSN: 1869-1447
Titre abrégé: Clin Neuroradiol
Pays: Germany
ID NLM: 101526693
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
15
02
2018
accepted:
11
09
2018
pubmed:
7
10
2018
medline:
21
4
2020
entrez:
7
10
2018
Statut:
ppublish
Résumé
The aim of the study was to investigate any metabolic changes on magnetic resonance spectroscopy (MRS) throughout the visual pathway of the brain in patients with glaucoma and a control group and correlate the results with clinical findings. A total of 87 patients were enrolled in the study, 30 healthy controls, 25 glaucoma, 16 suspected glaucoma (GS) and 16 ocular hypertension (OHT) patients. A single voxel MRS on TE 30 ms was performed by placing the volume of interest (VOI) on the corpus geniculatum laterale (CGL) and primary visual cortex (VC). Peak values of metabolites, such as N‑acetyl aspartate (NAA), creatine (Cr), choline (Cho) and Myo-inositol (Ins) were investigated on MRS. The MRS results were correlated with age, intraocular pressure (IOP), retinal nerve fiber length (RNFL), mean deviation (MD) and cup disk ratio (CD). The NAA values obtained from the CGL in glaucoma and GS cases were lower than the healthy control group. The Cho values at CGL in glaucoma were lower than GS and controls. There was a negative correlation between NAA values of the VC and CD in glaucoma cases. Additionally, there was a negative correlation between age and RNFL in both glaucoma and GS cases. The use of MRS can reveal neurodegeneration in CGL and VC in patients with glaucoma. Depiction of metabolic changes throughout the visual pathways via MRS will guide the treatment planning and follow-up in glaucoma and GS cases.
Identifiants
pubmed: 30291364
doi: 10.1007/s00062-018-0728-7
pii: 10.1007/s00062-018-0728-7
doi:
Substances chimiques
Aspartic Acid
30KYC7MIAI
N-acetylaspartate
997-55-7
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
615-621Références
Arch Ophthalmol. 1996 Mar;114(3):299-305
pubmed: 8600890
Eur Radiol. 2016 Dec;26(12):4404-4412
pubmed: 26943134
Prog Retin Eye Res. 2007 Jan;26(1):57-77
pubmed: 17158086
Lancet. 2017 Nov 11;390(10108):2183-2193
pubmed: 28577860
Lancet Glob Health. 2013 Dec;1(6):e339-49
pubmed: 25104599
Am J Ophthalmol. 2006 Oct;142(4):576-82
pubmed: 17011848
FASEB J. 1999 Jan;13(1):135-42
pubmed: 9872938
Radiology. 2009 Aug;252(2):496-501
pubmed: 19435941
Prog Brain Res. 2008;173:165-77
pubmed: 18929108
Bull World Health Organ. 2004 Nov;82(11):887-8
pubmed: 15640929
Exp Eye Res. 2009 Jan;88(1):65-70
pubmed: 18992243
Ophthalmology. 2014 Nov;121(11):2081-90
pubmed: 24974815
Eye (Lond). 2012 Aug;26(8):1044-51
pubmed: 22627479
Graefes Arch Clin Exp Ophthalmol. 2014 Jun;252(6):995-1000
pubmed: 24770532
Int J Ophthalmol. 2015 Oct 18;8(5):975-9
pubmed: 26558212
Invest Ophthalmol Vis Sci. 2009 Sep;50(9):4223-8
pubmed: 19407026
J Glaucoma. 2017 Feb;26(2):173-181
pubmed: 27661989
J Glaucoma. 2004 Jun;13(3):189-95
pubmed: 15118461
Br J Ophthalmol. 2006 Jun;90(6):674-8
pubmed: 16464969
Invest Ophthalmol Vis Sci. 2014 Apr 10;55(6):3468-76
pubmed: 24722700
Surv Ophthalmol. 1999 Jun;43 Suppl 1:S151-61
pubmed: 10416758
AJNR Am J Neuroradiol. 2012 Jan;33(1):128-34
pubmed: 22116110
PLoS One. 2013 Sep 03;8(9):e73208
pubmed: 24019910
PLoS One. 2013 Aug 29;8(8):e73197
pubmed: 24009739
Arch Ophthalmol. 2006 Jun;124(6):853-9
pubmed: 16769839
Invest Ophthalmol Vis Sci. 2000 Oct;41(11):3460-6
pubmed: 11006239